TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02299557
Drug: Oxymetazoline gel
Normalized name: oxymetazoline Nasal Gel
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline gel applied intra-anally once daily
Study: NCT00109395
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study: NCT00662831
Drug: Fragmin/ Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
Study: NCT00662831
Drug: Placebo for Fragmin/ Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
Study: NCT03360682
Drug: Lamivudine 300 MG
Normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 300 MG/day (48 weeks)
Study: NCT03360682
Drug: Abacavir 600 MG
Normalized name: abacavir 600 MG
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir 600 MG/day (48 weeks)
Study: NCT00109395
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study: NCT00109395
Drug: Lorazepam CI
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study: NCT03360682
Drug: Dolutegravir 50 mg
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir 50 MG/day (48 weeks)
Study: NCT03360682
Drug: Tenofovir Disoproxil 245Mg Tablet
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir 245 MG/day (48 weeks)
Study: NCT03360682
Drug: Emtricitabine 200 MG
Normalized name: emtricitabine 200 MG
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine 200 MG/day (48 weeks)
Study: NCT02322580
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01434901
Drug: Bethanechol (25 mg)
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study: NCT01434901
Drug: Bethanechol (50 mg)
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study: NCT01434901
Drug: Bethanechol (100 mg)
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study: NCT01734798
Drug: gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02964273
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan spray-dried, immediate release tablets
Study: NCT02964273
Drug: Tolvaptan Matching-placebo
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan matching-placebo tablets
Study: NCT00575055
Drug: Bapineuzumab 0.5 mg/kg
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study: NCT02205190
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01384565
Drug: G-CSF+EPO
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study: NCT04496908
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
Study: NCT02598687
Drug: TH-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
Study: NCT04072835
Drug: Etripamil NS
Normalized name: NS-2359
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
Study: NCT02598687
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/ml/min
Study: NCT02598687
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg/m2
Study: NCT00140179
Drug: valnoctamide
Normalized name: valnoctamide
DrugBank: Valnoctamide (DB13099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00042016
Drug: decitabine (5-aza-2'deoxycytidine)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00256828
Drug: didanosine + lamivudine + efavirenz
Normalized name: efavirenz / lamivudine / tenofovir disoproxil
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00564733
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00564733
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00564733
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00564733
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00575055
Drug: Bapineuzumab 1.0 m/kg
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study: NCT01453283
Drug: Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Normalized name: trabectedin Injection [Yondelis]
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00118976
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01579058
Drug: bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bisoprolol 5mg qd for 4 years
Study: NCT01709110
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01709110
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00462787
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01709110
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00037518
Drug: AMG 073
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02468687
Drug: N-methyl-pyrrolidone
Normalized name: N-methyl-pyrrolidone
DrugBank: Methyl pyrrolidone (DB12521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
Study: NCT00596557
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
Study: NCT00462787
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00462787
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00462787
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462787
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01963182
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01475643
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
Study: NCT01536431
Drug: Pro insulin peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
Study: NCT00045032
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Study: NCT00045032
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Study: NCT00191373
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00191373
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01536431
Drug: Pro insulin peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
Study: NCT01536431
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
Study: NCT00321165
Drug: taurolidine
Normalized name: Taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00845195
Drug: Olopatadine HCl Nasal Spray, 0.6%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
Study: NCT00845195
Drug: Azelastine HCl Nasal Spray, 0.1%
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
Study: NCT00667576
Drug: Maxacalcitol
Normalized name: Maxacalcitol
DrugBank: Maxacalcitol (DB06272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
Study: NCT00667576
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
Study: NCT03770208
Drug: Intervention: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Lidocaine bolus plus infusion. Weight based.
Study: NCT03602469
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
Study: NCT03602469
Drug: Bupivacaine-magnesium
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
Study: NCT03602469
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using propofol 1.5-2.5 mg/kg
Study: NCT03602469
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Study: NCT03602469
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg
Study: NCT04227275
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study: NCT04227275
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study: NCT02105610
Drug: desflurane, isoflurane, sevoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03632187
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept every weeks during 3 months
Study: NCT00209677
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00209677
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00006028
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006028
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00264641
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperinsulinaemic induced hypoglycaemia
Study: NCT00047021
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: high-dose cytarabine IV over 1 hour on days 1-5
Study: NCT00047021
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose mitoxantrone IV over 15-30 minutes on day 5.
Study: NCT00049439
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00049439
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00049439
Drug: procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT01089088
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)
Study: NCT01089088
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)
Study: NCT04227756
Drug: LSD
Normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
Study: NCT04227756
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 20 mg per os, single dose
Study: NCT04227756
Drug: Mescaline
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mescaline 300 mg or 500 mg per os, single dose
Study: NCT01089088
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)
Study: NCT00533533
Drug: docetaxel, oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1
Study: NCT02734810
Drug: Liprotamase Powder for Oral Solution
Normalized name: liprotamase protease
DrugBank: Liprotamase protease (DB16584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
Study: NCT01352312
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
Study: NCT01352312
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
Study: NCT01352312
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
Study: NCT00302172
Drug: ARQ 197
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted.
Study: NCT01871610
Drug: [18F]AV-45 PET amyloid binding imaging
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483054
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz 600 mg/day + stavudine + lamivudine
Study: NCT00483054
Drug: nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine 400 mg/day + stavudine +lamivudine
Study: NCT00903617
Drug: Niaspan
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg for 8 weeks
Study: NCT04538066
Drug: Bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Study: NCT02016625
Drug: Faldaprevir
Normalized name: Faldaprevir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02016625
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no